{"id":"W2980670340","doi":"10.1016/j.jtho.2019.10.006","title":"Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Ignyta; EMD Serono; Eisai; Natera; Ariad Pharmaceuticals; Genentech; Bristol-Myers Squibb; AstraZeneca; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Daiichi-Sankyo","keywords":"Ceritinib; Medicine; Nivolumab; Cohort; Internal medicine; Lung cancer; Gastroenterology; Cancer; Anaplastic lymphoma kinase; Oncology; Immunotherapy; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002678482,0.001548769,0.002342665,0.0004328006,0.000427454,0.001028868,0.0007359104,0.001063484,0.00122688],"category_scores_gemma":[0.00108016,0.0005190045,0.001626354,0.0004039524,0.000808686,0.0009888437,0.0002794184,0.002133021,0.0004800691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001470777,"about_ca_system_score_gemma":0.001357417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001364341,"about_ca_topic_score_gemma":0.002646661,"domain_scores_codex":[0.999184,0.0004084988,0.00005089678,0.0001668859,0.00009304433,0.00009677192],"domain_scores_gemma":[0.9990461,0.0001455837,0.0002114789,0.00007718512,0.00009687436,0.0004227333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7540514,0.06263332,0.02725079,0.0009732335,0.003772884,0.0003331955,0.0004664313,0.003175896,0.04166848,0.0001232653,0.00281977,0.1027315],"study_design_scores_gemma":[0.5304245,0.3979138,0.06069971,0.00004627221,0.001492192,0.0005280089,0.0001169394,0.002602538,0.003606867,0.0001254792,0.002378891,0.00006478796],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967737,0.001749215,0.0001793484,0.0001620823,0.00005325217,0.0004638434,0.0002945568,0.00003319305,0.0002908728],"genre_scores_gemma":[0.9966305,0.0009356383,0.0005730498,0.0002745362,0.0001142184,0.0003379647,0.0007176608,0.00001603381,0.0004003636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002678482,"threshold_uncertainty_score":0.01416534,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02181959936904216,"score_gpt":0.4505129397924997,"score_spread":0.4286933404234576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}